|1.||Boothman, David A: 16 articles (10/2010 - 03/2003)|
|2.||Bey, Erik A: 12 articles (10/2010 - 01/2005)|
|3.||Gao, Jinming: 11 articles (10/2010 - 01/2005)|
|4.||Choi, Yung Hyun: 8 articles (01/2015 - 03/2003)|
|5.||Dong, Ying: 7 articles (10/2010 - 09/2006)|
|6.||Park, Heon Joo: 7 articles (01/2009 - 01/2005)|
|7.||Reinicke, Kathryn E: 7 articles (07/2007 - 03/2003)|
|8.||Song, Chang W: 6 articles (03/2008 - 01/2005)|
|9.||Bentle, Melissa S: 6 articles (07/2007 - 04/2005)|
|10.||Bornmann, William G: 5 articles (05/2010 - 01/2005)|
12/15/2014 - "These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells."
04/01/2008 - "Metabolism by RBCs may play a role in clearance of ARQ 501 from the blood compartment in cancer patients."
01/07/2015 - "Interestingly, the small molecule beta-lapachone, which is currently in clinical trials for cancer, is among the potent inhibitors, thus suggesting possible new cellular targets for its therapeutic effects. "
12/15/2014 - "Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent."
06/01/2013 - "Beta-lapachone (β-Lap; 3,4-dihydro-2, 2-dimethyl-2H-naphthol[1, 2-b]pyran-5,6-dione) is a novel anti-cancer drug under phase I/II clinical trials. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2005 - "Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1."
04/01/2008 - "ARQ 501 formulated with hydroxypropyl-beta-cyclodextrin has successfully completed phase I clinical trials and is currently in several phase II human clinical trials for the treatment of pancreatic cancer, head and neck cancer, and leiomyosarcoma. "
01/01/2005 - "We hypothesized that beta-lapachone, a novel 1,2-naphthoquinone with potential antitumor activity in cancer cells expressing elevated levels of NQO1, would induce cytotoxicity in pancreatic cancer cells, wherein this two-electron reductase was recently found elevated. "
07/15/2007 - "beta-Lapachone (beta-lap; also known as ARQ 501), currently in phase II clinical trials for the treatment of pancreatic cancer, causes a novel caspase- and p53-independent cell death in cancer cells overexpressing NAD(P)H:quinone oxidoreductase-1 (NQO1). "
|4.||Chagas Disease (American Trypanosomiasis)
08/01/2008 - "These triazole derivatives of nor-beta-lapachone emerge as interesting new lead compounds in drug development for Chagas disease."
08/01/2008 - "[1,2,3]-Triazole derivatives of nor-beta-lapachone were synthesized and assayed against the infective bloodstream trypomastigote form of Trypanosoma cruzi, the etiological agent of Chagas disease. "
05/01/2010 - "In continuing our screening program of naphthoquinone activity against Trypanosoma cruzi, the aetiological agent of Chagas' disease, new beta-lapachone-based 1,2,3-triazoles, 3-arylamino-nor-beta-lapachones, 3-alkoxy-nor-beta-lapachones and imidazole anthraquinones were synthesised and evaluated against bloodstream trypomastigote forms of the parasite. "
01/01/1999 - "cruzi and in experimental Chagas disease (murine model): alkyllysophospholipids; 5-amino-imidazole-4-carboxamides; bisbenzyl-isoquinolines; cruzipain (crucein) inhibitors; Gossipol; phenothiazines; d) drugs effective in vitro without other reported effects, acridines, actinomycin D, Crystal Violet (gentian violet), diterpenes (Mikania obtusata); N,N'-dimethyl-2-propen-1-amine, epoxidienthiol carbamates, Fe-chelators, guanyl hydrazones, o-naphthoquinones (beta-lapachone); quinoids (miconidine; tingenone); Olivacine, phenazine methosulfate, phenoxi-phenoxyl drugs, Proadifen, pyridinium azolate betaines, sesquiterpenes (Lychophora sp), sesquiterpene lactones, tetrahydrocarbazoles, DL-alpha-trifluoromethylarginine, triphenylmetane dyes. "
04/01/2010 - "Treatment with beta-lapachone cleared the yeast from the spleen and liver, and the fungal burden decreased approximately 10(4) times in the lungs and brain 14 days after infection when compared to the PBS group (P < 0.05). "
04/01/2010 - "Seven days after infection, the mice were divided into groups and treated daily with beta-lapachone (10 mg/kg, iv) for 7 (N = 6) and 14 days (N = 10). "
04/01/2010 - "The in vivo antifungal activity of the naphthoquinone beta-lapachone against disseminated infection by Cryptococcus neoformans was investigated. "
04/01/2010 - "Antifungal activity of the naphthoquinone beta-lapachone against disseminated infection with Cryptococcus neoformans var. neoformans in dexamethasone-immunosuppressed Swiss mice."
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)